Oncotarget is the scientific journal to follow

In a world where information is a valuable resource, there are plenty of places to look for accurate information about various types of subject. However, rarely can you find blogs and online news channels that include up-to-date and detailed news about the recent scientific discoveries and researches. Oncotarget is one of those rare occasions.

Being a Journal focused on oncology, this online news provider updates users about the most recent discoveries that are happening in the scientific field. Those include updates in the development of the studies of cancer, reviews, and analysis of tests ran in labs and even the positive effects of the nuclear BAP1 in differentiating malignant pleural mesothelioma and lung cancer.

While Oncotarget makes its focus the oncological field, they also have news sections that branch to other areas of medicine as well. The most notable ones are the Immunology and Microbiology Section where they publish papers about researches in the body’s immunity system; as well as a dedicated section for publishing news about aging and diseases that come with it like Alzheimer’s and hypertension. Download output styles at Endnote.com.

The journal has already won the very honorable “Breakthrough Prize,” a noble reward to any publisher and one of their previous members of the Editorial even won a Nobel Prize (Andrew Schally).

The creators and leading editors of the journal are Mikhail Blagosklonny and Andrei V. Gudkov. The material started getting published when the journal was created in 2010, and it has been spreading the news about many fields of medicine since then. More than 200 papers were published since the creation, and they can all be found on the official website or in the US National Library of Medicine.

Oncotarget’s ranking as the primary choice for oncological research and newsfeed is dedicated to what any other journal in the scientific field strives to achieve: They provide insightful, up-to-date and constructive reviews of what is happening in the industry. The best part of the journal is that it is an online newsfeed that is free to access without the need for a paid subscription or membership. It is available to the public in every country around the globe. After all, their goal is to spread the news about oncology, not restrain it from the community. Read more about Oncotarget journal at Bioxbio.

Mikhail Blagosklonny – the undisputed Oncologist

Mr. Mikhail Blagosklonny is an undisputed scientist and a professor of oncology who currently works at RPCI (Roswell Park Cancer Institute). He earned both his master degree in internal medicine and Ph.D. in cardiology and experimental medicine from First Pavlov State Medical University. Before joining Roswell Park Cancer Institute, Mikhail was an associate professor at the New York Medical College. Furthermore, Mikhail worked as a scientist at the Ordway Research Institute, where most of his research were focusing on cancer treatment, anti-aging drugs, aging mechanism, and cancer therapies. Perhaps, Blagosklonny is a passionate advocate of the cancer drug known as Rapamycin. He even developed a hypothesis on the role of TOR signaling in aging and cancer treatment. According to the hypothesis, Rapamycin drug can prolong the life of a human being.

Mikhail Blagosklonny serves as a chief editor to several publications such as Cell Cycle and Oncotarget. He also works as an associate editor of the editorial board of Cancer Therapy and Biology. He understands that it is not a miracle to have a society that is free from aging and cancer effects. Because of this reason, Mikhail has dedicated most of his time in conducting more research in oncology study. In addition to his hypothesis, Blagosklonny zeroes in cellular biology, molecular biology, tumor suppressors, clinical investigation, ontogenesis, and anti-cancer therapeutics. Also, Mikhail has made a lot of contributions to the science journals. He believes that through journals, people can be aware of the things that are happening in their life. Mr. Mikhail Blagosklonny has written more than 300 articles. Most of his publications are about cell cyclotherapy, aging hyperfunction, and chemotherapeutic engineering.

Visit ResearchGate.Net to know more about Mikhail’s latest work.